CTRI/2019/02/017825进行中(未招募)未知
Rotasiil® vaccine effectiveness, rotavirus gastroenteritis and intussusception surveillance study in Jharkhand, India - RVEIS
试验速览
- 阶段
- 未知
- 状态
- 进行中(未招募)
- 发起方
- PATH
- 入组人数
- 1,422
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •I.Rotavirus Gastroenteritis Surveillance
- •1.Parent/LAR has provided written informed consent.
- •2.Present to one of the surveillance sites for treatment of AGE.
- •3.Are <5 years of age.
- •4.Produce a stool sample during the first 48 hours after presentation and are either treated with oral or intravenous fluids at the Emergency Department and discharged home or admitted to the hospital and treated with oral rehydration or intravenous fluids.
- •II.Vaccine Effectiveness Case-Control Evaluation
- •1.Meet the inclusion criteria and case definition for the RVGE surveillance program plus the eligible to have received at least one dose of vaccine prior to illness, i.e. age 8 weeks or older and born after February 24, 2018 (i.e., 6 weeks prior to the initial launch of Rotasiil® in Jharkhand).
- •2.Are <2 years of age
- •3.Residence in the state of Jharkhand.
- •III.Intussusception Surveillance:
- •1.Parent/LAR has provided written informed consent.
- •2.Are <2 years of age
- •3.Born after February 24, 2018
- •4.Meet the case definition for intussusception using the Level 1 Brighton criteria.
- •IV.Cost of illness study:
- •1.Enrolled into either the rotavirus gastroenteritis surveillance or intussusception surveillance programs, as applicable (are <5 years of age for rotavirus AGE surveillance and < 2 years of age for IS surveillance)
- •2.Parent willing to provide information to fill the questionnaire.
排除标准
- •I.Rotavirus Gastroenteritis Surveillance
- •1.Are 5 or more years of age
- •2. Unable to contact parent/LAR to obtain written informed consent.
- •3.Admitted to another hospital for >24 hours (and subsequently transferred to the current hospital).
- •II.Vaccine Effectiveness Case-Control Evaluation
- •1.Are age-ineligible to have received vaccine.
- •2.Illness onset is less than 2 weeks following initial vaccination
- •3.Vaccination record cannot be obtained either through the vaccination card or other records
- •4.Are >2 years of age
- •5.Participants with hospital acquired gastroenteritis
- •6.Participants in whom rotavirus vaccination is contraindicated
- •7.Parent/LAR unable to provide written informed consent.
- •III.Intussusception surveillance
- •1.Parent or LAR unwilling or unable to provide written informed consent.
- •2.If vaccination status cannot be confirmed
- •IV.Cost of illness study
- •1.Parent or LAR unwilling or unable to provide written informed consent.
研究者
相似试验
已完成
不适用
Safety and efficacy of rotavirus vaccine in infants admitting NICU; comparison between RV1 and RV5.Infants in NICJPRN-UMIN000016458Fujita Health University School of Medicine. Dept. of Pediatrics40
招募中
4 期
Immune response and safety of a mixed regimen of rotavirus vaccines (Rotavac and Rotasiil)CTRI/2018/08/015317Ministry of Health and Family Welfare
已完成
1 期
Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel SyndromeShort Bowel SyndromeNCT00767364Children's Hospital of Michigan8
已完成
3 期
Dose Confirmation Efficacy Study (V260-007)Rotavirus InfectionsNCT00092443Merck Sharp & Dohme LLC1,312
已完成
3 期
Rotavirus Efficacy and Safety Trial (REST)(V260-006)Rotavirus InfectionsNCT00090233Merck Sharp & Dohme LLC69,274
